ARMP

Armata Pharmaceuticals, Inc. (ARMP) 10Y Growth Potential Analysis (2026)

Invetso Score: 3.1/10 — Weak · Last Updated: 2026-09-01

Monthly Update
Overall Score3.13.1
Change0

Revenue Growth Drivers

Score: 3.2 (Weak)

ARMP lacks disclosed five-year revenue, EPS, or FCF CAGR data, limiting evidence of repeatable compounding versus peers with proven multi-year growth trajectories.

Very high R&D intensity at 7.8x revenue suggests heavy reinvestment, but it has not yet translated into durable revenue scaling or peer-leading commercialization.

Negative ROIC of -47.4% indicates capital deployed so far has destroyed value, which weakens the case for efficient long-term revenue expansion relative to peers.

No segmentation concentration data is provided, so there is no evidence of a scalable commercial base or repeatable customer expansion engine versus better-diversified peers.

Market Tailwinds

Score:

The available filings-based metrics do not show a validated demand tailwind, so growth must rely on future execution rather than demonstrated market pull versus peers.

ARMP’s negative operating economics imply that any addressable-market opportunity has not yet been converted into durable revenue growth, unlike stronger peer platforms.

The company’s cash conversion cycle of -135.4 days may support working-capital efficiency, but it does not by itself prove sustained end-market expansion.

Without disclosed segment or geographic mix, there is no evidence of broadening market access that would support multi-year revenue compounding versus peers.

Scalability Expansion

Score:

Capex at 11.3% of revenue is not especially heavy, but the absence of positive cash generation limits reinvestment capacity for scalable expansion versus peers.

Negative interest coverage and negative EV/EBITDA indicate the current operating base is not yet self-funding, which constrains compounding through internal capital formation.

The company’s high R&D spend could create future optionality, but current filings do not show a scalable commercialization model or repeatable expansion economics.

Compared with peers that already convert investment into positive returns, ARMP’s present scale-up profile remains early and structurally unproven.

Constraints Limitations

Score:

Negative ROIC and negative interest coverage are structural constraints because they indicate the business is not yet generating returns sufficient to fund durable expansion.

The lack of disclosed historical growth metrics prevents confirmation of a stable compounding base, which lowers confidence in long-term scalability versus peers.

Extremely high EV-to-sales at 149.4x suggests the market is pricing growth that current operating performance has not yet validated, increasing execution pressure.

Absent evidence of positive operating leverage, ARMP remains constrained by commercialization risk and capital efficiency limits relative to stronger growth peers.

Overall Score

Score:

ARMP’s long-term growth capacity appears structurally constrained because heavy R&D spending and low capex have not yet produced positive returns, scalable revenue evidence, or self-funding expansion.

Score Driver: Negative ROIC

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Armata Pharmaceuticals, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →